Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15266025rdf:typepubmed:Citationlld:pubmed
pubmed-article:15266025lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:15266025lifeskim:mentionsumls-concept:C0014609lld:lifeskim
pubmed-article:15266025lifeskim:mentionsumls-concept:C0458827lld:lifeskim
pubmed-article:15266025lifeskim:mentionsumls-concept:C0026682lld:lifeskim
pubmed-article:15266025lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:15266025lifeskim:mentionsumls-concept:C0037083lld:lifeskim
pubmed-article:15266025lifeskim:mentionsumls-concept:C0012472lld:lifeskim
pubmed-article:15266025lifeskim:mentionsumls-concept:C0031727lld:lifeskim
pubmed-article:15266025lifeskim:mentionsumls-concept:C0387583lld:lifeskim
pubmed-article:15266025lifeskim:mentionsumls-concept:C1710082lld:lifeskim
pubmed-article:15266025lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:15266025lifeskim:mentionsumls-concept:C0439596lld:lifeskim
pubmed-article:15266025lifeskim:mentionsumls-concept:C0127400lld:lifeskim
pubmed-article:15266025pubmed:issue2lld:pubmed
pubmed-article:15266025pubmed:dateCreated2004-7-21lld:pubmed
pubmed-article:15266025pubmed:abstractTextWe reported recently that interleukin (IL)-1beta exposure resulted in a prolonged increase in MUC5AC mucin production in normal, well differentiated, human tracheobronchial epithelial (NHTBE) cell cultures, without significantly increasing MUC5AC mRNA (Am J Physiol 286:L320-L330, 2004). The goal of the present study was to elucidate the signaling pathways involved in IL-1beta-induced MUC5AC production. We found that IL-1beta increased cyclooxygenase-2 (COX-2) mRNA expression and prostaglandin (PG) E(2) production and that the COX-2 inhibitor celecoxib suppressed IL-1beta-induced MUC5AC production. Addition of exogenous PGE(2) to NHTBE cultures also increased MUC5AC production and IL-1beta-induced Muc5ac hypersecretion in tracheas from wild-type but not from COX-2-/- mice. NHTBE cells expressed all four E-prostanoid (EP) receptor subtypes and misoprostol, an EP2 and EP4 agonist, increased MUC5AC production, whereas sulprostone, an EP1 and EP3 agonist, did not. Furthermore, specific protein kinase A (PKA) inhibitors blocked IL-1beta and PGE(2)-induced MUC5AC production. However, neither inhibition of epidermal growth factor receptor (EGFR) activation with the tyrosine kinase inhibitor 4-(3-chloroanilino)-6,7-dimethoxyquinazoline HCl (AG-1478) or EGFR blocking antibody nor inhibition of extracellular signal-regulated kinase/P-38 mitogen activated protein kinases with specific inhibitors blocked IL-1beta stimulation of MUC5AC mucin production. We also observed that tumor necrosis factor (TNF)-alpha, platelet activating factor (PAF), and lipopolysaccharide (LPS) induced COX-2 and increased MUC5AC production that was blocked by celecoxib, suggesting a common signaling pathway of inflammatory mediator-induced MUC5AC production in NHTBE cells. We conclude that the induction of MUC5AC by IL-1beta, TNF-alpha, PAF, and LPS involves COX-2- generated PGE(2), activation of EP2 and/or EP4 receptor(s), and cAMP-PKA-mediated signaling.lld:pubmed
pubmed-article:15266025pubmed:languageenglld:pubmed
pubmed-article:15266025pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:citationSubsetIMlld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15266025pubmed:statusMEDLINElld:pubmed
pubmed-article:15266025pubmed:monthAuglld:pubmed
pubmed-article:15266025pubmed:issn0026-895Xlld:pubmed
pubmed-article:15266025pubmed:authorpubmed-author:NettesheimPau...lld:pubmed
pubmed-article:15266025pubmed:authorpubmed-author:LangenbachRob...lld:pubmed
pubmed-article:15266025pubmed:authorpubmed-author:KooJa-SeokJSlld:pubmed
pubmed-article:15266025pubmed:authorpubmed-author:PeddadaShyama...lld:pubmed
pubmed-article:15266025pubmed:authorpubmed-author:BonnerJamesJlld:pubmed
pubmed-article:15266025pubmed:authorpubmed-author:GrayThomasTlld:pubmed
pubmed-article:15266025pubmed:authorpubmed-author:LoftinCharles...lld:pubmed
pubmed-article:15266025pubmed:issnTypePrintlld:pubmed
pubmed-article:15266025pubmed:volume66lld:pubmed
pubmed-article:15266025pubmed:ownerNLMlld:pubmed
pubmed-article:15266025pubmed:authorsCompleteYlld:pubmed
pubmed-article:15266025pubmed:pagination337-46lld:pubmed
pubmed-article:15266025pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:meshHeadingpubmed-meshheading:15266025...lld:pubmed
pubmed-article:15266025pubmed:year2004lld:pubmed
pubmed-article:15266025pubmed:articleTitleInterleukin-1beta-induced mucin production in human airway epithelium is mediated by cyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling.lld:pubmed
pubmed-article:15266025pubmed:affiliationLaboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA. grayt@niehs.nih.govlld:pubmed
pubmed-article:15266025pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15266025lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15266025lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15266025lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15266025lld:pubmed